Passage Bio Inc at TD Cowen Healthcare Conference Transcript
Welcome back to one of the last sessions of TD Cowen's 46th Annual Healthcare Conference. I'm Brendan Smith, one of the Tools DX analysts here at TD, and it is my pleasure to introduce CEO of Passage Bio, Will Chou. He's going to give a brief presentation upfront and then, excuse me, as is the case for most of our fireside chats and presentation slots throughout the conference, if you got any questions, maybe kind of hold off to towards of -- towards the latter end, or if you want to send them to me at [email protected] and kind of work them into Q&A at the back end, but for now, I will hand it off to Will.
Okay, thank you, Brendan. Excited to close things out for us at the conference. So, Will Chou, CEO of Passage Bio, I'm going to be talking today primarily about the first thing listed here, which is our clinical stage AAV program in FTD with the granular mutation that we believe is quite differentiated in this market.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
